EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4580	((544/122,295,317) or (514/231.8, 235.8,252.14,274)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/10/25 15:17

NPL Search Notes

		Results
13.	TITLE-ABSTR-KEY(inhibiting or inhibition) and TITLE-ABSTR-KEY(catenin) *[All Sources(- All Sciences -)]*	1025
12.	TITLE-ABSTR-KEY(inhibiting or inhibition) and TITLE-ABSTR-KEY(tau protein) *[All Sources(- All Sciences -)]*	295
11.	TITLE-ABSTR-KEY(lowering) and TITLE-ABSTR-KEY(blood glucose levels) *[All Sources(- All Sciences -)]*	337
10.	TITLE-ABSTR-KEY(glycogen synthesis) and TITLE-ABSTR-KEY(enhancing) *[All Sources(- All Sciences -)]*	37
9.	TITLE-ABSTR-KEY(gsk-3) and TITLE-ABSTR-KEY(hypertrophy) *[All Sources(- All Sciences -)]*	10
8.	TITLE-ABSTR-KEY(gsk-3) and TITLE-ABSTR-KEY(cardiomycete hypertrophy) *[All Sources(- All Sciences -)]*	0
7.	TITLE-ABSTR-KEY(gsk-3) and TITLE-ABSTR-KEY(multiple sclerosis) *[All Sources(- All Sciences -)]*	0
6.	TITLE-ABSTR-KEY(gsk-3) and TITLE-ABSTR-KEY(amyotrophic lateral sclerosis or als) *[All Sources(- All Sciences -)]*	6
5.	TITLE-ABSTR-KEY(gsk-3) and TITLE-ABSTR-KEY(diabetes) *[All Sources(- All Sciences -)]*	71
4.	(TITLE-ABSTR-KEY(src) and TITLE-ABSTR-KEY(inhibiting or inhibition or inhibitor)) AND (TITLE-ABSTR-KEY(gsk-3) and TITLE-ABSTR-KEY(inhibiting or inhibition or inhibitor)) *[All Sources(- All Sciences -)]*	7
3.	TITLE-ABSTR-KEY(src) and TITLE-ABSTR-KEY(inhibiting or inhibition or inhibitor) *[All Sources(- All Sciences -)]*	6899
2.	TITLE-ABSTR-KEY(gsk-3) and TITLE-ABSTR-KEY(inhibiting or inhibition or inhibitor) *[All Sources(- All Sciences -)]*	593
1.	TITLE-ABSTR-KEY(aurora-2) and TITLE-ABSTR-KEY(inhibiting or inhibition or inhibitor) *[All Sources(- All Sciences -)]*	4

C:\Program Files\Stnexp\Queries\10632428.str



chain nodes :
7 9 10 11 40
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
chain bonds :
5-9 7-40 9-10 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-18 15-16 16-17 17-18 19-20 19-23 20-21 21-22 22-23 24-25
24-28 25-26 26-27 26-29 27-28 27-32 29-30 30-31 31-32
exact/norm bonds :
5-9 7-40 9-10 10-11 14-15 14-18 15-16 16-17 17-18 19-20 19-23 20-21 21-22 22-23 24-25
24-28 25-26 26-27 26-29 27-28 27-32 29-30 30-31 31-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 14 : 19 : 24 :

G1:[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS 11:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 40:CLASS

=>
Uploading C:\Program Files\Stnexp\Queries\10632428.str

chain nodes :
7 9 10 11 40
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
chain bonds :
5-9 7-40 9-10 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-18 15-16 16-17 17-18 19-20 19-23 20-21 21-22 22-23 24-25 24-28 25-26 26-27 26-29 27-28 27-32 29-30 30-31 31-32
exact/norm bonds :
5-9 7-40 9-10 10-11 14-15 14-18 15-16 16-17 17-18 19-20 19-23 20-21 21-22 22-23 24-25 24-28 25-26 26-27 26-29 27-28 27-32 29-30 30-31 31-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 14 : 19 : 24 :

G1:[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS 11:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 40:CLASS

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 09:18:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       85 TO ITERATE

100.0% PROCESSED       85 ITERATIONS                              10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1147 TO     2253
PROJECTED ANSWERS:              11 TO      389

L2            10 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 09:19:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1696 TO ITERATE

100.0% PROCESSED     1696 ITERATIONS                             179 ANSWERS
SEARCH TIME: 00.00.01

L3           179 SEA SSS FUL L1

=> => s l3
L4           13 L3

=> d l4 1-13 bib,ab,hitstr
```

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:758896 CAPLUS
DN 145:241171
TI The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function
AU Gizatullin, Farid; Yao, Xao; Kung, Victor; Harding, Matthew W.; Loda, Massimo; Shapiro, Geoffrey I.
CS Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
SO Cancer Research (2006), 66(15), 7668-7677
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB VX-680 is a potent inhibitor of Aurora kinases that induces the accumulation of cells with ≥4N DNA content, followed by cell death. Here, we define the role of p53 and p21Waf1/Cip1 in cell cycle perturbations following exposure to VX-680. Endoreduplication and apoptosis in response to VX-680 are limited in A549 and MCF-7 cells expressing wild-type p53, and markedly enhanced in cells lacking p53, including those engineered to express the HPV16-E6 oncoprotein or short interfering RNA pools targeting p53. In contrast, endoreduplication and apoptosis occur in the p53 wild-type cell lines, RKO and U2OS. The difference in response to VX-680 among these cell lines correlates with the timing of induction of p21Waf1/Cip1 and its ability to inhibit cyclin E-cdk2 activity. In A549 cells, VX-680 induces the expression of p53 and p21Waf1/Cip1 within 24 h, with consequent inhibition of cyclin E-cdk2, and reduction of retinoblastoma protein phosphorylation, limiting endoreduplication. In RKO and U2OS cells, the induction of p21Waf1/Cip1 is delayed and associated with higher residual cyclin E-cdk2 kinase activity and retinoblastoma protein phosphorylation, followed by progressive endoreduplication and apoptosis. Abrogation of p21Waf1/Cip1 expression by short interfering RNA targeting in A549 cells results in a substantial increase in the degree of endoreduplication, whereas inducible expression of p21Waf1/Cip1 in p53-neg. NCI-H1299 cells inhibits VX-680-induced endoreduplication and cell death. These data suggest that the integrity of the p53-p21Waf1/Cip1-dependent postmitotic checkpoint governs the response to Aurora kinase inhibition. Although cells with intact checkpoint function arrest with 4N DNA content, those with compromised checkpoint function are more likely to undergo endoreduplication followed by eventual apoptosis.
IT 639089-54-6, VX-680
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function)
RN 639089-54-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:681435 CAPLUS
DN 145:137879
TI Pyrimidine derivative kinase modulators and therapeutic use
IN Chen, Jeff; Dalrymple, Lisa Esther; Epshteyn, Sergey; Forsyth, Timothy Patrick; Huynh, Tai Phat; Ibrahim, Mohamed Abdulkader; Leahy, James W.; Lewis, Gary Lee; Mann, Grace; Mann, Lary W.; Noguchi, Robin Tammie; Ridgway, Brian Hugh; Sangalang, Joan Cruz; Schnepp, Kevin Luke; Shi, Xian; Takeuchi, Craig Stacy; Williams, Matthew Alan; Nuss, John; Cheung, Atwood K.
PA Exelixis, Inc., USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006074057	A2	20060713	WO 2005-US47402	20051228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-640439P P 20041230
US 2005-704863P P 20050801
OS MARPAT 145:137879
AB The invention provides pyrimidine derivs. and methods for inhibition of kinases, more specifically IGF1R kinases. The invention also provides compds. and methods for inhibition of wildtype Abl. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Preparation of pyrimidine derivs. is included.
IT 898278-97-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrimidine derivative kinase modulators and therapeutic use)
RN 898278-97-2 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(3-methyl-1H-pyrazol-5-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)


Me
N
NH
NH
Me
N
N
N
N
S
NH
C
O

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:495929 CAPLUS
DN 145:8181
TI Preparation of pyrazolylamino pyrimidine derivatives as Aurora A/B kinase inhibitors
IN Xiao, Xiao-Yi; Patel, Dinesh V.
PA Miikana Therapeutics, Inc., USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006055831	A2	20060526	WO 2005-US41945	20051117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-629176P P 20041117
OS MARPAT 145:8181
AB Title compds. represented by the formula I [wherein ring A = (un)substituted pyrazolyl; W = (un)substituted amino; X = carboxyl, carbonyl ester or aminoacyl; Y = O, S, SO, SO2 or NR; R = H or (un)substituted alkyl; Ar = (un)substituted (hetero)aryl; R2 = H or alkyl; R3 = H, (un)substituted alkyl, alkoxy, etc.; and isomers, prodrugs, and pharmaceutically acceptable salts thereof] were prepared as Aurora A/B kinase inhibitors. For example, II was provided in a multi-step synthesis starting from potassium salt of 5-nitroorotic acid. Selected I inhibited Aurora B enzyme by 100%, and I were tested for Aurora kinase whole cell cytoxicity using human tumor-derived cell lines, HCT116 or MCF7. Pharmaceutical formulations were given also. Thus, I and their pharmaceutical compns. are useful for the prevention or treatment of diseases associated with protein kinases, especially diseases associated with Aurora-A (Aurora-2) and Aurora-B (Aurora-1), such as cancer.
IT 888020-14-2P 888020-15-3P 888020-18-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolylamino pyrimidine derivs. as Aurora A/B kinase inhibitors)
RN 888020-14-2 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-15-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-18-6 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 888020-16-4P 888020-19-7P 888020-20-0P
888020-21-1P 888020-22-2P 888020-23-3P
888020-24-4P 888020-27-7P 888020-28-8P
888020-29-9P 888020-30-2P 888020-31-3P
888020-32-4P 888020-33-5P 888020-34-6P
888020-35-7P 888020-36-8P 888020-37-9P
888020-38-0P 888020-39-1P 888020-40-4P
888020-41-5P 888020-42-6P 888020-43-7P
888020-44-8P 888020-45-9P 888020-46-0P

888020-47-1P 888020-48-2P 888020-49-3P
888020-50-6P 888020-51-7P 888020-52-8P
888020-53-9P 888020-54-0P 888020-55-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolylamino pyrimidine derivs. as Aurora A/B kinase inhibitors)

RN 888020-16-4 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-N-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 888020-19-7 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-N-[2-(dimethylamino)ethyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 888020-20-0 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]sulfonyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-21-1 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]sulfinyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-22-2 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-23-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-24-4 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, tetrahydro-2H-pyran-4-yl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-27-7 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-28-8 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 2-(methylthio)ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-29-9 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phe

nyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, cyclohexyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 888020-30-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-N-(2-methoxyethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 888020-31-3 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[5-amino-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinylcarbonyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-32-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[5-amino-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-thiomorpholinylcarbonyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-33-5 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-34-6 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 1-methyl-4-piperidinyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-35-7 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 2-(1-piperidinyl)ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-36-8 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-37-9 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-38-0 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-4-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-39-1 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-40-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[5-amino-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(1-piperidinylcarbonyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-41-5 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-42-6 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-N-(3-methoxypropyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-43-7 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-44-8 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl] thio]-N-(1,1-dimethylethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-45-9 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl] thio]-N-(2-furanylmethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-46-0 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-47-1 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-48-2 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-N-(2-methoxy-1-methylethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-49-3 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-N-cyclohexyl-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-50-6 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]

thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-(tetrahydro-2H-pyran-4-yl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-51-7 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]
thio]-N-(1-methyl-4-piperidinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-52-8 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]
thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-N-(2,2,2-trifluoroethyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-53-9 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-54-0 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-amino-2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 888020-55-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[5-amino-4-[(4-methyl-1-piperazinyl)carbonyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 888020-13-1P 888020-17-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolylamino pyrimidine derivs. as Aurora A/B kinase inhibitors)

RN 888020-13-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitro-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 888020-17-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[[4-[(cyclopropylcarbonyl)amino]phenyl]thio]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitro-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:459089 CAPLUS
DN 145:43907
TI Targeting Aurora Kinases for the Treatment of Prostate Cancer
AU Lee, Edmund Chun Yu; Frolov, Anna; Li, Rile; Ayala, Gustavo; Greenberg, Norman M.
CS Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Pharmacology, University of Washington, Seattle, WA, 98109, USA
SO Cancer Research (2006), 66(10), 4996-5002
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB Inappropriate expression of the Aurora kinases can induce aberrant mitosis, centrosome irregularities, and chromosomal instability, which lead to aneuploidy and cell transformation. Here, we report that Aurora-A and Aurora-B are highly expressed in primary human and mouse prostate cancers and prostate cancer cell lines. In clin. samples, levels of Aurora-A and Aurora-B were significantly elevated in prostatic intraepithelial neoplasia lesions and prostate tumors when compared with the non-neoplastic samples. Interestingly, expression of Aurora-A in non-neoplastic prostates correlated with seminal vesicle invasion (ρ = 0.275, P = 0.0169) and in prostate tumor with pos. surgical margins (ρ = 0.265, P = 0.0161). In addition, nuclear expression of Aurora-B in prostatic intraepithelial neoplasia lesions correlated with clin. staging of the tumor (ρ = -0.4, P = 0.0474) whereas cytoplasmic expression in tumors correlated with seminal vesicle invasion (ρ = 0.282, P = 0.0098). Cell lines and primary tumors derived from the TRAMP model were also found to express high levels of Aurora-A and Aurora-B. When human PC3, LNCaP, and mouse C1A cells were treated with the potent Aurora kinase inhibitor VX680, which attenuates phosphorylation of histone H3, cancer cell survival was reduced. VX680 could further reduce cell viability >2-fold when used in combination with the chemotherapy drug doxorubicin. Our findings support a functional relationship between Aurora kinase expression and prostate cancer and the application of small-mol. inhibitors in therapeutic modalities.
IT 639089-54-6, VX680
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Aurora-A kinase and Aurora-B kinase are highly expressed in primary human and mouse prostate cancers and prostate cancer cell lines and application of small-mol. inhibitors in therapeutic modalities)
RN 639089-54-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:55725 CAPLUS
DN 144:166361
TI Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680
AU Young, Matthew A.; Shah, Neil P.; Chao, Luke H.; Seeliger, Markus; Milanov, Zdravko V.; Biggs, William H., III; Treiber, Daniel K.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.; Sawyers, Charles L.; Kuriyan, John
CS Departments of Molecular and Cell Biology and Chemistry, Howard Hughes Medical Institute, The University of California, Berkeley, CA, USA
SO Cancer Research (2006), 66(2), 1007-1014
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB We present a high-resolution (2.0 Å) crystal structure of the catalytic domain of a mutant form of the Abl tyrosine kinase (H396P; Abl-1a numbering) that is resistant to the Abl inhibitor imatinib. The structure is determined in complex with the small-mol. inhibitor VX-680 (Vertex Pharmaceuticals, Cambridge, MA), which blocks the activity of various imatinib-resistant mutant forms of Abl, including one (T315I) that is resistant to both imatinib and BMS-354825 (dasatinib), a dual Src/Abl inhibitor that seems to be clin. effective against all other imatinib-resistant forms of BCR-Abl. VX-680 is shown to have significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. The Abl kinase domain bound to VX-680 is not phosphorylated on the activation loop in the crystal structure but is nevertheless in an active conformation, previously unobserved for Abl and inconsistent with the binding of imatinib. The adoption of an active conformation is most likely the result of synergy between the His396Pro mutation, which destabilizes the inactive conformation required for imatinib binding, and the binding of VX-680, which favors the active conformation through hydrogen bonding and steric effects. VX-680 is bound to Abl in a mode that accommodates the substitution of isoleucine for threonine at residue 315 (the "gatekeeper" position). The avoidance of the innermost cavity of the Abl kinase domain by VX-680 and the specific recognition of the active conformation explain the effectiveness of this compound against mutant forms of BCR-Abl, including those with mutations at the gatekeeper position.
IT 639089-54-6D, VX 680, complexes with Abl kinase domain
RL: PRP (Properties)
(structural and biochem. anal. address mol. basis of VX-680 inhibitory activity against imatinib-resistant mutant forms of human BCR-Abl)
RN 639089-54-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:781086 CAPLUS
DN 143:222029
TI Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
AU Carter, Todd A.; Wodicka, Lisa M.; Shah, Neil P.; Velasco, Anne Marie; Fabian, Miles A.; Treiber, Daniel K.; Milanov, Zdravko V.; Atteridge, Corey E.; Biggs, William H., III; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Mehta, Shamal A.; Patel, Hitesh K.; Pao, William; Sawyers, Charles L.; Varmus, Harold; Zarrinkar, Patrick P.; Lockhart, David J.
CS Ambit, Inc., San Diego, CA, 92121, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2005), 102(31), 11011-11016
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
AB To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it is important to address the emergence of drug resistance in treated patients. Mutant forms of BCR-ABL, KIT, and the EGF receptor (EGFR) have been found that confer resistance to the drugs imatinib, gefitinib, and erlotinib. The mutations weaken or prevent drug binding, and interestingly, one of the most common sites of mutation in all three kinases is a highly conserved "gatekeeper" threonine residue near the kinase active site. We have identified existing clin. compds. that bind and inhibit drug-resistant mutant variants of ABL, KIT, and EGFR. We found that the Aurora kinase inhibitor VX-680 and the p38 inhibitor BIRB-796 inhibit the imatinib- and BMS-354825-resistant ABL(T315I) kinase. The KIT/FLT3 inhibitor SU-11248 potently inhibits the imatinib-resistant KIT(V559D/T670I) kinase, consistent with the clin. efficacy of SU-11248 against imatinib-resistant gastrointestinal tumors, and the EGFR inhibitors EKB-569 and Cl-1033, but not GW-572016 and ZD-6474, potently inhibit the gefitinib- and erlotinib-resistant EGFR(L858R/T790M) kinase. EKB-569 and Cl-1033 are already in clin. trials, and our results suggest that they should be considered for testing in the treatment of gefitinib/erlotinib-resistant non-small cell lung cancer. The results highlight the strategy of screening existing clin. compds. against newly identified drug-resistant mutant variants to find compds. that may serve as starting points for the development of next-generation drugs, or that could be used directly to treat patients that have acquired resistance to first-generation targeted therapy.
IT 639089-54-6, VX-680
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases for screening of antitumor agents)
RN 639089-54-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:140796 CAPLUS
DN 142:240444
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3
IN Bebbington, David; Charrier, Jean-damien; Golec, Julian; Miller, Andrew; Knegtel, Ronald
PA UK
SO U.S. Pat. Appl. Publ., 164 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005038023	A1	20050217	US 2003-632428	20030801
PRAI US 2003-632428		20030801		

OS MARPAT 142:240444
AB The title compds. I [Z1 = N, CR8; Z2 = N, CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliphatic, (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl; or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepared For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β, AURORA-2, CDK-2, ERK2, AKT, and human Src kinase. I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).
IT 438203-38-4P 438203-43-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
RN 438203-38-4 CAPLUS
CN Acetamide, N-[4-[[4-(4-methoxyphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-43-1 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 438203-35-1P 438203-36-2P 438203-41-9P
438203-45-3P 438203-48-6P 438205-29-9P
438205-30-2P 438205-31-3P 438205-32-4P
438205-34-6P 438205-36-8P 438205-38-0P
438205-40-4P 438205-41-5P 438205-42-6P
438205-43-7P 438205-44-8P 438205-46-0P
438205-47-1P 438205-48-2P 438205-49-3P
438205-50-6P 438205-51-7P 438205-52-8P
438205-53-9P 438205-54-0P 438205-55-1P
438205-56-2P 438205-57-3P 438205-58-4P
438205-59-5P 438205-60-8P 438205-61-9P
438205-62-0P 438205-63-1P 438205-64-2P
438205-65-3P 438205-66-4P 438205-67-5P
438205-68-6P 438205-69-7P 438205-70-0P
438205-71-1P 438205-72-2P 438205-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
RN 438203-35-1 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-36-2 CAPLUS

CN 4-Pyrimidinamine, 2-[[(4-methoxyphenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-41-9 CAPLUS

CN Acetamide, N-[4-[[4-[4-[3-(dimethylamino)propoxy]phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-45-3 CAPLUS

CN Propanamide, N-[4-[[4-(hydroxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-48-6 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-29-9 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-30-2 CAPLUS
CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-31-3 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-32-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-34-6 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-36-8 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-38-0 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-40-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-41-5 CAPLUS
CN 4-Pyrimidinamine, 6-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-42-6 CAPLUS
CN 4-Pyrimidinamine, 6-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-43-7 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-44-8 CAPLUS
CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-46-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-47-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-48-2 CAPLUS
CN 1-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-49-3 CAPLUS
CN Ethanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-50-6 CAPLUS
CN Acetamide, N-[4-[[4-(2-methylphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-51-7 CAPLUS
CN Butanamide, 3-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-52-8 CAPLUS
CN Acetamide, N-[4-[[5-methyl-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-53-9 CAPLUS
CN Acetamide, N-[4-[[4-[3-(acetylamino)phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-54-0 CAPLUS
CN 2-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-55-1 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-56-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-57-3 CAPLUS
CN 4,6-Pyrimidinediamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(2-methoxyethyl)-N'-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-58-4 CAPLUS
CN 4-Pyrimidinamine, 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-59-5 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-60-8 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-61-9 CAPLUS
CN Acetamide, N-[4-[[4-(1,1-dimethylethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-62-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-63-1 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-64-2 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-65-3 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(2-methoxyethyl)amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-66-4 CAPLUS
CN Morpholine, 4-[[4-[[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-67-5 CAPLUS
CN Propanamide, N-[4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-68-6 CAPLUS
CN Benzoic acid, 4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-69-7 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-70-0 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-71-1 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(2-naphthalenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-72-2 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-73-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, butyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:161480 CAPLUS
DN 140:399485
TI VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
AU Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M.
CS Vertex Pharmaceuticals (Europe) Limited, Abingdon, Oxfordshire, OX14 4RY, UK
SO Nature Medicine (New York, NY, United States) (2004), 10(3), 262-267
CODEN: NAMEFI; ISSN: 1078-8956
PB Nature Publishing Group
DT Journal
LA English
AB The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis. Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis. Here we report the discovery of a highly potent and selective small-mol. inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types. This compound causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses. Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.
IT 639089-54-6, VX 680
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VX-680, a potent and selective small-mol. inhibitor of Aurora kinases, suppresses tumor growth in vivo)
RN 639089-54-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:2878 CAPLUS
DN 140:59657
TI Processes for preparing 6-pyrazolylpyrimidines as inhibitors of protein kinase, in particular Aurora kinases, by nucleophilic substitution
IN Charrier, Jean-Damien; Mazzei, Francesca; Kay, David; Miller, Andrew
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000833	A1	20031231	WO 2003-US19266	20030619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004049032	A1	20040311	US 2003-464430	20030618
	CA 2489824	AA	20031231	CA 2003-2489824	20030619
	AU 2003245568	A1	20040106	AU 2003-245568	20030619
	EP 1517905	A1	20050330	EP 2003-739195	20030619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012443	A	20050510	BR 2003-12443	20030619
	JP 2006501176	T2	20060112	JP 2004-515904	20030619
	NO 2005000144	A	20050321	NO 2005-144	20050111
	JP 2005320351	A2	20051117	JP 2005-211959	20050721
PRAI	US 2002-390658P	P	20020620		
	US 2002-411609P	P	20020918		
	JP 2004-515904	A3	20030619		
	WO 2003-US19266	W	20030619		

OS MARPAT 140:59657
AB The present invention provides a facile process for the preparation of tri-and tetra-substituted pyrimidines, as inhibitors of protein kinases, especially Aurora kinases, by nucleophilic substitution of pyrimidines containing a leaving group with a nucleophile in an organic solvent, and optionally in the presence of a base. Pyrimidines of the invention are of the formula I [wherein Q, T = independently O, S, NR; R = independently H, (un)substituted aliphatic group; optionally NR and a radical adjacent to the N = 3-7 membered monocyclic, or 8-10 (un)saturated membered bicyclic, bearing 0-3 addnl. heteroatoms selected from N, O or S; Rx = UR5; R5 = halo, NO, CN, R or Ar; U = independently a valence bond, alkylidene chain, with up to two methylene units of U optionally and independently replaced by O, S, SO, SO2, NRSO, SONR, NR, CO, CO2, NRCO, NRC(O)O, NRCONR, NRSO2NR, CONR, OCONR, CR:NNR, CR:NO; Ar = independently (un)substituted 3-7 membered monocyclic or 8-10 (un)saturated membered bicyclic, bearing 0-4 heteroatoms independently selected from N, O or S; Ry = N(R1), OR1, SR1; R1 = independently R, or (un)substituted 3-7 membered monocyclic or 8-10 (un)saturated membered bicyclic, bearing 0-4 heteroatoms independently selected from N, O or S; Rz1 = (un)substituted aliphatic group or 3-8

Common Inv

not available for 102(e)

ODP

membered monocyclic, or 8-10 membered bicyclic, or 10-12 membered (un)saturated tricyclic ring bearing 0-4 heteroatoms independently selected from O, N, or S; Rz2 = (un)substituted aliphatic group or 3-8 membered monocyclic, or (un)saturated 8-10 membered bicyclic bearing 0-4 heteroatoms independently selected from N, o or S]. The advantages include min. number of chemical and separation steps, use of available starting materials and simple reaction media, an easy to scale-up and cheap process. For example, II was prepared by successive nucleophilic substitutions of 2-methylsulfonyl-4,6-dichloropyrimidine (preparation given) with cyclopropanecarboxylic acid N-(4-sulfanylphenyl)amide in tert-BuOH, with 3-amino-5-methylpyrazole in DMF in the presence of DIPEA/NaI, and with N-methylpiperazine in excess. Selected II were found inhibitors of Aurora-1, Aurora-2, Aurora-3, and FLT-3 kinases in vivo, in vitro and in a cell line assay (no data). Thus, selected II and their pharmaceutical compns. are useful for treating or lessening the severity of Aurora-mediated diseases or conditions such as cancer.

IT 639090-55-4P, Cyclopropanecarboxylic acid N-[4-[[4-chloro-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl]sulfanyl]phenyl]amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of 6-pyrazolylpyrimidines, as inhibitors of protein kinase, by nucleophilic substitution)

RN 639090-55-4 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[4-chloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 639089-55-7P 639089-56-8P 639089-57-9P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of 6-pyrazolylpyrimidines, as inhibitors of protein kinase, by nucleophilic substitution)

RN 639089-55-7 CAPLUS

CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-56-8 CAPLUS
CN Propanamide, 2,2-dimethyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-57-9 CAPLUS
CN Propanamide, N-[4-[[4-[4-(1-methylethyl)-1-piperazinyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 639090-56-5, Ethanecarboxylic acid N-[4-[[4-chloro-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl]sulfanyl]phenyl]amide

RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparation of 6-pyrazolylpyrimidines, as inhibitors of protein kinase, by nucleophilic substitution)

RN 639090-56-5 CAPLUS

CN Propanamide, N-[4-[[4-chloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 639090-38-3P 639090-39-4P 639090-40-7P
639090-42-9P 639090-44-1P 639090-46-3P
639090-48-5P 639090-49-6P 639090-50-9P
639090-51-0P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor, pyrimidine product; process for preparation of 6-pyrazolylpyrimidines, as inhibitors of protein kinase, by nucleophilic substitution)

RN 639090-38-3 CAPLUS

CN Propanedioic acid, compd. with N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 141-82-2
CMF C3 H4 O4

$HO_2C-CH_2-CO_2H$

RN 639090-39-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 639090-40-7 CAPLUS
CN Butanedioic acid, compd. with N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 639090-42-9 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 639090-44-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 639090-46-3 CAPLUS
CN Propanoic acid, 3-sulfo-, compd. with N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6

CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 44826-45-1
CMF C3 H6 O5 S



RN 639090-48-5 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 639090-49-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 639090-50-9 CAPLUS
CN Propanamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 639090-51-0 CAPLUS

CN Propanamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-73-9
CMF C22 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 75-75-2
CMF C H4 O3 S



IT 639089-54-6P, Cyclopropanecarboxylic acid N-[4-[[4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl]sulfanyl]phenyl]amide 639089-58-0P, N-[4-[[4-(5-Methyl-2H-pyrazol-3-ylamino)-6-(4-propylpiperazin-1-yl)pyrimidin-2-yl]sulfanyl]phenyl]propionamide 639089-59-1P 639089-60-4P 639089-61-5P 639089-62-6P 639089-63-7P 639089-64-8P 639089-65-9P 639089-66-0P 639089-67-1P 639089-68-2P 639089-69-3P 639089-70-6P 639089-71-7P 639089-72-8P, Cyclopropanecarboxylic acid N-[4-[[4-(4-methyl-4-oxopiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl]sulfanyl]phenyl]amide 639089-73-9P 639090-36-1P 639090-37-2P 639090-58-7P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; process for preparation of 6-pyrazolylpyrimidines, as inhibitors of protein kinase, by nucleophilic substitution)

RN 639089-54-6 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 639089-58-0 CAPLUS

CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-propyl-1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-59-1 CAPLUS
CN Propanamide, N-[4-[[4-(4-ethyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-60-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-61-5 CAPLUS
CN Propanamide, N-[4-[[4-[4-(cyclopropylmethyl)-1-piperazinyl]-6-[(5-methyl-

1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-62-6 CAPLUS
CN Propanamide, N-[4-[[4-(4-cyclopropyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-63-7 CAPLUS
CN Propanamide, N-[4-[[4-[4-(1,1-dimethylethyl)-1-piperazinyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-64-8 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-ethyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-65-9 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-66-0 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-ethyl-1-piperazinyl)-6-[(5-ethyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-67-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(4-ethyl-1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 639089-68-2 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-69-3 CAPLUS
CN Acetamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-70-6 CAPLUS
CN Propanamide, 2,2-dimethyl-N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-71-7 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-ethyl-1H-pyrazol-3-yl)amino]-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-72-8 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-4-oxido-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-73-9 CAPLUS

CN Propanamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 639090-36-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 639090-37-2 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 639090-58-7 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 639089-54-6
CMF C23 H28 N8 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 7664-93-9
CMF H2 O4 S



IT 639089-74-0P 639089-75-1P 639089-76-2P
639089-77-3P 639089-78-4P 639089-79-5P
639089-80-8P 639089-81-9P 639089-82-0P
639089-83-1P 639089-84-2P 639089-85-3P
639089-86-4P 639089-87-5P 639089-88-6P
639089-89-7P 639089-90-0P 639089-91-1P
639089-92-2P 639089-93-3P 639089-94-4P
639089-95-5P 639089-96-6P 639089-98-8P
639090-00-9P 639090-01-0P 639090-02-1P
639090-03-2P 639090-04-3P 639090-05-4P
639090-06-5P 639090-07-6P 639090-08-7P
639090-09-8P 639090-10-1P 639090-11-2P
639090-12-3P 639090-13-4P 639090-14-5P
639090-15-6P 639090-16-7P 639090-17-8P
639090-18-9P 639090-19-0P 639090-20-3P
639090-21-4P 639090-22-5P 639090-23-6P
639090-24-7P 639090-25-8P 639090-26-9P
639090-27-0P 639090-30-5P 639090-35-0P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(substituted pyrimidine product; process for preparation of 6-pyrazolylpyrimidines, as inhibitors of protein kinase, by nucleophilic substitution)

RN 639089-74-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-75-1 CAPLUS
CN Propanamide, N-[4-[[4-[(2-aminoethyl)amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-76-2 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-[[2-(1-piperidinyl)ethyl]amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-77-3 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-78-4 CAPLUS
CN Propanamide, N-[4-[[4-[methyl[2-(methylamino)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-79-5 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(1-piperidinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 639089-80-8 CAPLUS
CN Propanamide, N-[4-[[4-(hexahydro-1H-1,4-diazepin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-81-9 CAPLUS
CN Propanamide, N-[4-[[4-[[2-(dimethylamino)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-82-0 CAPLUS
CN Propanamide, N-[4-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-83-1 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-thiomorpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-84-2 CAPLUS
CN Propanamide, N-[4-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-85-3 CAPLUS
CN Carbamic acid, [1-[6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-4-pyrimidinyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-86-4 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[4-(phenylmethyl)-1-piperazinyl]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-87-5 CAPLUS
CN Propanamide, N-[4-[[4-(4-amino-1-piperidinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-88-6 CAPLUS
CN Propanamide, N-[4-[[4-(3-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-89-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-4-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-90-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-phenyl-1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-91-1 CAPLUS
CN Propanamide, N-[4-[[4-(3,5-dimethyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-92-2 CAPLUS
CN Propanamide, N-[4-[[4-(3-amino-1-pyrrolidinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-93-3 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(4-methyl-1-piperidinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-94-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-[[2-(1-piperidinyl)ethyl]amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-95-5 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-[[2-(4-morpholinyl)ethyl]amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-96-6 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-piperidinylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639089-98-8 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-00-9 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-morpholinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-01-0 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-02-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-(1-methylethyl)-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-03-2 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-04-3 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[[2-(1-piperidinyl)ethyl]amino]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-05-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-06-5 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(1-piperazinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-07-6 CAPLUS
CN Propanamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-08-7 CAPLUS
CN Propanamide, N-[4-[[4-(4-morpholinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-09-8 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[[2-(dimethylamino)ethyl]amino]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-10-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[[2-(4-morpholinyl)ethyl]amino]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-11-2 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-(2-cyanoethyl)-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-12-3 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(1H-pyrazol-3-ylamino)-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-13-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(2R)-bicyclo[2.2.2]oct-2-ylamino]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-14-5 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(2S)-bicyclo[2.2.2]oct-2-ylamino]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-15-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(3,4-dihydro-2(1H)-isoquinolinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-16-7 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-(methylsulfonyl)-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-17-8 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-ethyl-1-piperazinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-18-9 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(4-propyl-1-piperazinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-19-0 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-[2-(methylsulfonyl)ethyl]-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-20-3 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(3-methyl-1-piperazinyl)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-21-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-22-5 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-(phenylmethyl)-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-23-6 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-[4-(phenylmethyl)-1-piperazinyl]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-24-7 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-25-8 CAPLUS
CN Propanamide, N-[4-[[4-(methylphenylamino)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 639090-26-9 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-(diethylamino)-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-27-0 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[4-(1,1-dimethylethyl)-1-piperazinyl]-6-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-30-5 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-chloro-1H-pyrazol-3-yl)amino]-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 639090-35-0 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:615605 CAPLUS
DN 137:169539
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian M. C.; Miller, Andrew; Knegtel, Ronald
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 335 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002062789	A1	20020815	WO 2001-US51031	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2432222	AA	20020815	CA 2001-2432222	20011219
CA 2432303	AA	20020829	CA 2001-2432303	20011219
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432223	AA	20020906	CA 2001-2432223	20011219
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003004161 X	A1	20030102	US 2001-26975 X	20011219
US 6653300 X	B2	20031125		
US 2003036543	A1	20030220	US 2001-25164 — Parent	20011219
US 6664247 — ODP	B2	20031216		
US 2003055068	A1	20030320	US 2001-26967 X	20011219
US 6989385 X	B2	20060124		

Common Inv.

US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345927	A1	20030924	EP 2001-994510	20011219
EP 1345927	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518703	T2	20040624	JP 2002-563142	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
NZ 526471	A	20050826	NZ 2001-526471	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613
NO 2003002736	A	20030818	NO 2003-2736	20030616
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321

	AU 2006201265	A1	20060427	AU 2006-201265	20060321
	AU 2006201391	A1	20060427	AU 2006-201391	20060404
PRAI	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2000-232795P X	P	20000915		
	AU 2001-90944	A3	20010914		
	AU 2001-91013	A3	20010914		
	AU 2001-94558	A3	20010914		
	AU 2001-96871	A3	20010914		
	AU 2001-96875	A3	20010914		
	EP 2001-971082	A3	20010914		
	US 2001-952671	A3	20010914		
	US 2001-955601	A3	20010914		
	EP 2001-273861	A	20011219		
	EP 2001-994323	A3	20011219		
	JP 2002-557938	A3	20011219		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	WO 2001-US51031	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

Parent

OS MARPAT 137:169539

AB 285 Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(R6')2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6', R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6')2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared However, the claims pertain only to 3-(2-amino-4-pyrimidinylamino)-1H-pyrazoles, i.e. Z1 = Z2 = N, and Q = NH. I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438203-38-4P, [2-(4-Acetamidophenylsulfanyl)-6-(4-methoxyphenyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
438203-43-1P, [6-Methoxycarbonyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-38-4 CAPLUS

CN Acetamide, N-[4-[[4-(4-methoxyphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-43-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 438203-35-1P, [2-(4-Acetamidophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-36-2P, [2-(4-Methoxybenzylsulfanyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-41-9P, [2-(4-Acetamidophenylsulfanyl)-6-[4-(3-dimethylaminopropoxy)phenyl]pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-45-3P, [6-Hydroxymethyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-48-6P, [2-(4-Acetamidophenylsulfanyl)-6-(morpholin-4-yl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-29-9P, (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(naphthalen-2-ylsulfanyl)-6-phenylpyrimidin-4-yl]amine 438205-30-2P, (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(3-methoxycarbonylphenylsulfanyl)-6-phenylpyrimidin-4-yl]amine 438205-31-3P, (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(naphthalen-2-

ylsulfanyl)pyrimidin-4-yl]amine 438205-32-4P,
(5-Cyclopropyl-1H-pyrazol-3-yl)[5,6-dimethyl-2-(naphthalen-2-
ylsulfanyl)pyrimidin-4-yl]amine 438205-34-6P,
(5-Cyclopropyl-1H-pyrazol-3-yl)[5-methyl-2-(naphthalen-2-
ylsulfanyl)pyrimidin-4-yl]amine 438205-36-8P,
(5-Cyclopropyl-1H-pyrazol-3-yl)[6-methyl-2-(naphthalen-2-
ylsulfanyl)pyrimidin-4-yl]amine 438205-38-0P,
(5-Cyclopropyl-1H-pyrazol-3-yl)[6-(morpholin-4-yl)-2-(naphthalen-2-
ylsulfanyl)pyrimidin-4-yl]amine 438205-40-4P,
(5-Cyclopropyl-1H-pyrazol-3-yl)[6-(1-methylpiperazin-4-yl)-2-(naphthalen-2-
ylsulfanyl)pyrimidin-4-yl]amine 438205-41-5P,
[6-(2,6-Dimethylphenyl)-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl](5-
methyl-1H-pyrazol-3-yl)amine 438205-42-6P, [6-(2-Methylphenyl)-2-
(naphthalen-2-ylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
438205-43-7P, (5-Methyl-1H-pyrazol-3-yl)[2-(naphthalen-2-
ylsulfanyl)-6-phenylpyrimidin-4-yl]amine 438205-44-8P,
[2-(4-Isobutyrylylaminophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-
pyrazol-3-yl)amine 438205-46-0P, (5-Methyl-1H-pyrazol-3-yl)[6-
phenyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl]amine
438205-47-1P, [2-(4-Cyclopropylcarbonylaminophenylsulfanyl)-6-
phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-48-2P
, (5-Methyl-1H-pyrazol-3-yl)[6-phenyl-2-[[4-(propylsulfonylamino)phenyl]su
lfanyl]pyrimidin-4-yl]amine 438205-49-3P, [2-(4-
Ethanesulfonylaminophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-
pyrazol-3-yl)amine 438205-50-6P, [2-(4-Acetamidophenylsulfanyl)-
6-(2-methylphenyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
438205-51-7P, [2-(4-Isobutylcarbonylaminophenylsulfanyl)-6-
phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-52-8P
, [2-(4-Acetamidophenylsulfanyl)-5-methyl-6-phenylpyrimidin-4-yl](5-methyl-
1H-pyrazol-3-yl)amine 438205-53-9P, [6-(3-Acetamidophenyl)-2-(4-
acetamidophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
438205-54-0P, [2-(4-Isopropylsulfonylaminophenylsulfanyl)-6-
phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-55-1P
, [2-[[4-(2-Dimethylaminoacetylamino)phenyl]sulfanyl]-6-phenylpyrimidin-4-
yl](5-methyl-1H-pyrazol-3-yl)amine 438205-56-2P
438205-57-3P 438205-58-4P, [2-Benzylsulfanyl-6-(4-
methylpiperazin-1-yl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
438205-59-5P 438205-60-8P 438205-61-9P,
[2-(4-Acetamidophenylsulfanyl)-6-tert-butylpyrimidin-4-yl](5-methyl-1H-
pyrazol-3-yl)amine 438205-62-0P, (5-Cyclopropyl-1H-pyrazol-3-
yl)[6-phenyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl]amine
438205-63-1P 438205-64-2P, (5-Methyl-1H-pyrazol-3-yl)[2-
[[4-(morpholinosulfonyl)benzyl]sulfanyl]-6-morpholin-4-ylpyrimidin-4-
yl]amine 438205-65-3P, [6-(2-Methoxyethylamino)-2-[[4-
(morpholinosulfonyl)benzyl]sulfanyl]pyrimidin-4-yl](5-methyl-1H-pyrazol-3-
yl)amine 438205-66-4P, [6-(4-Methylpiperazin-1-yl)-2-[[4-
(morpholinosulfonyl)benzyl]sulfanyl]pyrimidin-4-yl](5-methyl-1H-pyrazol-3-
yl)amine 438205-67-5P, [6-Methoxymethyl-2-(4-
propionylaminophenylsulfanyl)pyrimidin-4-yl]-(5-methyl-1H-pyrazol-3-
yl)amine 438205-68-6P, [2-(4-Methoxycarbonylphenylsulfanyl)-6-
methoxymethylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
438205-69-7P, [2-(3,5-Dimethoxybenzylsulfanyl)-6-morpholin-4-
ylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-70-0P,
[2-(3,5-Dimethoxybenzylsulfanyl)-6-pyrrolidin-4-ylpyrimidin-4-yl](5-methyl-
1H-pyrazol-3-yl)amine 438205-71-1P, (5-Methyl-1H-pyrazol-3-yl)[6-
morpholin-4-yl-2-(naphthalene-2-ylmethylsulfanyl)pyrimidin-4-yl]amine
438205-72-2P, [2-(4-Acetamidophenylsulfanyl)pyrimidin-4-yl](5-
methyl-1H-pyrazol-3-yl)amine 438205-73-3P,

[6-(1-Butoxycarbonyl)-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-35-1 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-36-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(4-methoxyphenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-41-9 CAPLUS
CN Acetamide, N-[4-[[4-[4-[3-(dimethylamino)propoxy]phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-45-3 CAPLUS
CN Propanamide, N-[4-[[4-(hydroxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-48-6 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-29-9 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-30-2 CAPLUS
CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-31-3 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-32-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-34-6 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-36-8 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-38-0 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-40-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-41-5 CAPLUS
CN 4-Pyrimidinamine, 6-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-42-6 CAPLUS
CN 4-Pyrimidinamine, 6-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-43-7 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-44-8 CAPLUS
CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-46-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-47-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-48-2 CAPLUS
CN 1-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-49-3 CAPLUS
CN Ethanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-50-6 CAPLUS
CN Acetamide, N-[4-[[4-(2-methylphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-51-7 CAPLUS
CN Butanamide, 3-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-52-8 CAPLUS
CN Acetamide, N-[4-[[5-methyl-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-53-9 CAPLUS
CN Acetamide, N-[4-[[4-[3-(acetylamino)phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-54-0 CAPLUS
CN 2-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-55-1 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-56-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-57-3 CAPLUS
CN 4,6-Pyrimidinediamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(2-methoxyethyl)-N'-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-58-4 CAPLUS
CN 4-Pyrimidinamine, 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-59-5 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-60-8 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-61-9 CAPLUS
CN Acetamide, N-[4-[[4-(1,1-dimethylethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-62-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-63-1 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-64-2 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-65-3 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(2-methoxyethyl)amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-66-4 CAPLUS
CN Morpholine, 4-[[4-[[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-67-5 CAPLUS
CN Propanamide, N-[4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-68-6 CAPLUS
CN Benzoic acid, 4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-69-7 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-70-0 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-71-1 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(2-naphthalenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-72-2 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-73-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, butyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:575069 CAPLUS
DN 137:109292
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3,for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Golec, Julian; Kay, David; Knegtel, Ronald; Patel, Sanjay
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 337 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

Common Inv

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059111	A2	20020801	WO 2001-US51120	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1698627	A1	20060906	EP 2006-10798	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2432131	AA	20020801	CA 2001-2432131	20011219
	CA 2432303	AA	20020829	CA 2001-2432303	20011219
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2432223	AA	20020906	CA 2001-2432223	20011219
	WO 2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004161	A1	20030102	US 2001-26975	20011219
	US 6653300 X	B2	20031125		
	US 2003036543	A1	20030220	US 2001-25164 — Parent	20011219
	US 6664247 ODP	B2	20031216		
	US 2003055068	A1	20030320	US 2001-26967	20011219
	US 6989385 X	B2	20060124		

US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345926	A2	20030924	EP 2001-993360	20011219
EP 1345926	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016493	A	20030930	BR 2001-16493	20011219
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526468	A	20040326	NZ 2001-526468	20011219
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004517926	T2	20040617	JP 2002-559413	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002670	A	20030815	NO 2003-2670	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321

	AU 2006201264	A1	20060427	AU 2006-201264	20060321
	AU 2006201265	A1	20060427	AU 2006-201265	20060321
	AU 2006201391	A1	20060427	AU 2006-201391	20060404
PRAI	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2000-232795P	P	20000915		
	AU 2001-90944	A3	20010914		
	AU 2001-91013	A3	20010914		
	AU 2001-94558	A3	20010914		
	AU 2001-96871	A3	20010914		
	AU 2001-96875	A3	20010914		
	EP 2001-971082	A3	20010914		
	US 2001-952671	A3	20010914		
	US 2001-955601	A3	20010914		
	EP 2001-273861	A	20011219		
	EP 2001-994323	A3	20011219		
	JP 2002-557938	A3	20011219		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US50312	W	20011219		
	WO 2001-US51120	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 137:109292

AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438203-38-4P 438203-43-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as

protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-38-4 CAPLUS

CN Acetamide, N-[4-[[4-(4-methoxyphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-43-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 438203-35-1P 438203-36-2P 438203-41-9P
438203-45-3P 438203-48-6P 438205-29-9P
438205-30-2P 438205-31-3P 438205-32-4P
438205-34-6P 438205-36-8P 438205-38-0P
438205-40-4P 438205-41-5P 438205-42-6P
438205-43-7P 438205-44-8P 438205-46-0P
438205-47-1P 438205-48-2P 438205-49-3P
438205-50-6P 438205-51-7P 438205-52-8P
438205-53-9P 438205-54-0P 438205-55-1P
438205-56-2P 438205-57-3P 438205-58-4P
438205-59-5P 438205-60-8P 438205-61-9P
438205-62-0P 438205-63-1P 438205-64-2P
438205-65-3P 438205-66-4P 438205-67-5P
438205-68-6P 438205-69-7P 438205-70-0P
438205-71-1P 438205-72-2P 438205-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-35-1 CAPLUS

CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-36-2 CAPLUS

CN 4-Pyrimidinamine, 2-[[(4-methoxyphenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-41-9 CAPLUS

CN Acetamide, N-[4-[[4-[4-[3-(dimethylamino)propoxy]phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-45-3 CAPLUS
CN Propanamide, N-[4-[[4-(hydroxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-48-6 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-29-9 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-30-2 CAPLUS
CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-31-3 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-32-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-34-6 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-36-8 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-38-0 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-40-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-41-5 CAPLUS
CN 4-Pyrimidinamine, 6-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-42-6 CAPLUS
CN 4-Pyrimidinamine, 6-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-43-7 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-44-8 CAPLUS
CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-46-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-47-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-48-2 CAPLUS
CN 1-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-49-3 CAPLUS
CN Ethanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-50-6 CAPLUS
CN Acetamide, N-[4-[[4-(2-methylphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-51-7 CAPLUS
CN Butanamide, 3-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-52-8 CAPLUS
CN Acetamide, N-[4-[[5-methyl-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-53-9 CAPLUS
CN Acetamide, N-[4-[[4-[3-(acetylamino)phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-54-0 CAPLUS
CN 2-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-55-1 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-56-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-57-3 CAPLUS
CN 4,6-Pyrimidinediamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(2-methoxyethyl)-N'-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-58-4 CAPLUS
CN 4-Pyrimidinamine, 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-59-5 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-60-8 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-61-9 CAPLUS
CN Acetamide, N-[4-[[4-(1,1-dimethylethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-62-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-63-1 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-64-2 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-65-3 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(2-methoxyethyl)amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-66-4 CAPLUS
CN Morpholine, 4-[[4-[[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-67-5 CAPLUS
CN Propanamide, N-[4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-68-6 CAPLUS
CN Benzoic acid, 4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-69-7 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-70-0 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-71-1 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(2-naphthalenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-72-2 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-73-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, butyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:555487 CAPLUS
DN 137:125169
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3
IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian; Miller, Andrew; Knegtel, Ronald
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

Same Inv. Same Prov. Priority

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057259	A2	20020725	WO 2001-US49401	20011219
	WO 2002057259	A3	20030424		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1698627	A1	20060906	EP 2006-10798	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2432129	AA	20020725	CA 2001-2432129	20011219
	CA 2432303	AA	20020829	CA 2001-2432303	20011219
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2432223	AA	20020906	CA 2001-2432223	20011219
	WO 2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004161	A1	20030102	US 2001-26975	20011219
	US 6653300	B2	20031125		
	US 2003036543	A1	20030220	US 2001-25164	20011219
	US 6664247	B2	20031216		
	US 2003055068	A1	20030320	US 2001-26967	20011219

US 6989385	B2	20060124		
US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1353916	A2	20031022	EP 2001-994323	20011219
EP 1353916	B1	20060920		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016411	A	20031111	BR 2001-16411	20011219
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004517894	T2	20040617	JP 2002-557938	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
NZ 526470	A	20060331	NZ 2001-526470	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002703	A	20030819	NO 2003-2703	20030613
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321

	AU 2006201263	A1	20060427	AU 2006-201263	20060321
	AU 2006201264	A1	20060427	AU 2006-201264	20060321
	AU 2006201265	A1	20060427	AU 2006-201265	20060321
	AU 2006201391	A1	20060427	AU 2006-201391	20060404
PRAI	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2000-232795P	P	20000915		
	AU 2001-90944	A3	20010914		
	AU 2001-91013	A3	20010914		
	AU 2001-94558	A3	20010914		
	AU 2001-96871	A3	20010914		
	AU 2001-96875	A3	20010914		
	EP 2001-971082	A3	20010914		
	US 2001-952671	A3	20010914		
	US 2001-955601	A3	20010914		
	EP 2001-273861	A	20011219		
	EP 2001-994323	A3	20011219		
	JP 2002-557938	A3	20011219		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US49401	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

Parent

OS MARPAT 137:125169

AB The title compds. I [Z1 = N, CR8; Z2 = N. CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliphatic, (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl; or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepared For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438203-38-4P 438203-43-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-38-4 CAPLUS

CN Acetamide, N-[4-[[4-(4-methoxyphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-43-1 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 438203-35-1P 438203-36-2P 438203-41-9P
438203-45-3P 438203-48-6P 438205-29-9P
438205-30-2P 438205-31-3P 438205-32-4P
438205-34-6P 438205-36-8P 438205-38-0P
438205-40-4P 438205-41-5P 438205-42-6P
438205-43-7P 438205-44-8P 438205-46-0P
438205-47-1P 438205-48-2P 438205-49-3P
438205-50-6P 438205-51-7P 438205-52-8P
438205-53-9P 438205-54-0P 438205-55-1P
438205-56-2P 438205-57-3P 438205-58-4P
438205-59-5P 438205-60-8P 438205-61-9P
438205-62-0P 438205-63-1P 438205-64-2P
438205-65-3P 438205-66-4P 438205-67-5P
438205-68-6P 438205-69-7P 438205-70-0P
438205-71-1P 438205-72-2P 438205-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
RN 438203-35-1 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-36-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(4-methoxyphenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-41-9 CAPLUS
CN Acetamide, N-[4-[[4-[4-[3-(dimethylamino)propoxy]phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-45-3 CAPLUS
CN Propanamide, N-[4-[[4-(hydroxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-48-6 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-29-9 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-30-2 CAPLUS
CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-31-3 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-32-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-34-6 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-36-8 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-38-0 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-40-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-41-5 CAPLUS
CN 4-Pyrimidinamine, 6-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-42-6 CAPLUS
CN 4-Pyrimidinamine, 6-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-43-7 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-44-8 CAPLUS
CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-46-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-47-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-48-2 CAPLUS
CN 1-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-49-3 CAPLUS
CN Ethanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-50-6 CAPLUS
CN Acetamide, N-[4-[[4-(2-methylphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-51-7 CAPLUS
CN Butanamide, 3-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-52-8 CAPLUS
CN Acetamide, N-[4-[[5-methyl-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-53-9 CAPLUS
CN Acetamide, N-[4-[[4-[3-(acetylamino)phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-54-0 CAPLUS
CN 2-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-55-1 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-56-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-57-3 CAPLUS
CN 4,6-Pyrimidinediamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(2-methoxyethyl)-N'-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-58-4 CAPLUS
CN 4-Pyrimidinamine, 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-59-5 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-60-8 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-61-9 CAPLUS
CN Acetamide, N-[4-[[4-(1,1-dimethylethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-62-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-63-1 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-64-2 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-65-3 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(2-methoxyethyl)amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-66-4 CAPLUS
CN Morpholine, 4-[[4-[[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-67-5 CAPLUS
CN Propanamide, N-[4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-68-6 CAPLUS
CN Benzoic acid, 4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-69-7 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-70-0 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-71-1 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(2-naphthalenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-72-2 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-73-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, butyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:487556 CAPLUS
DN 137:47221
TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3,for treatment of cancer, diabetes, and Alzheimer's disease
IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Everitt, Simon; Kay, David; Knegtel, Ronald; Patel, Sanjay
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 14

Common Inv

No 102(e) date !

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050065	A2	20020627	WO 2001-US49140	20011219
	WO 2002050065	A3	20021024		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1698627	A1	20060906	EP 2006-10798	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2432799	AA	20020627	CA 2001-2432799	20011219
	AU 2002034047	A5	20020701	AU 2002-34047	20011219
	CA 2432303	AA	20020829	CA 2001-2432303	20011219
	WO 2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2432223	AA	20020906	CA 2001-2432223	20011219
	WO 2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004161	A1	20030102	US 2001-26975	20011219
	US 6653300	B2	20031125		
	US 2003036543	A1	20030220	US 2001-25164 — Parent	20011219
	US 6664247 O>P	B2	20031216		

US 2003055068	A1	20030320	US 2001-26967	20011219
US 6989385	B2	20060124		
US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345925	A2	20030924	EP 2001-985059	20011219
EP 1345925	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004516291	T2	20040603	JP 2002-551561	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
NZ 526469	A	20051028	NZ 2001-526469	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002671	A	20030818	NO 2003-2671	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321

	AU 2006201263	A1	20060427	AU 2006-201263	20060321
	AU 2006201264	A1	20060427	AU 2006-201264	20060321
	AU 2006201265	A1	20060427	AU 2006-201265	20060321
	AU 2006201391	A1	20060427	AU 2006-201391	20060404
PRAI	US 2000-257887P	P	20001221	Prov. applns	
	US 2001-286949P	P	20010427		
	US 2000-232795P	P	20000915		
	AU 2001-90944	A3	20010914		
	AU 2001-91013	A3	20010914		
	AU 2001-94558	A3	20010914		
	AU 2001-96871	A3	20010914		
	AU 2001-96875	A3	20010914		
	EP 2001-971082	A3	20010914		
	US 2001-952671	A3	20010914		
	US 2001-955601	A3	20010914		
	EP 2001-273861	A	20011219		
	EP 2001-994323	A3	20011219		
	JP 2002-557938	A3	20011219		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US49140	W	20011219		
	WO 2001-US50312	W	20011219		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		

OS MARPAT 137:47221

AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438203-38-4P, [2-(4-Acetamidophenylsulfanyl)-6-(4-methoxyphenyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
438203-43-1P, [6-Methoxycarbonyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-

yl)amine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
RN 438203-38-4 CAPLUS
CN Acetamide, N-[4-[[4-(4-methoxyphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-43-1 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
IT 438203-35-1P, [2-(4-Acetamidophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-36-2P, [2-(4-Methoxybenzylsulfanyl)-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-41-9P, [2-(4-Acetamidophenylsulfanyl)-6-[4-(3-dimethylaminopropoxy)phenyl]pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-45-3P, [6-Hydroxymethyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438203-48-6P, [2-(4-Acetamidophenylsulfanyl)-6-(morpholin-4-yl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-29-9P, (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(naphthalen-2-ylsulfanyl)-6-phenylpyrimidin-4-yl]amine 438205-30-2P, (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(3-methoxycarbonylphenylsulfanyl)-6-phenylpyrimidin-4-yl]amine

438205-31-3P, (5-Cyclopropyl-1H-pyrazol-3-yl)[2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl]amine 438205-32-4P, (5-Cyclopropyl-1H-pyrazol-3-yl)[5,6-dimethyl-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl]amine 438205-34-6P, (5-Cyclopropyl-1H-pyrazol-3-yl)[5-methyl-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl]amine 438205-36-8P, (5-Cyclopropyl-1H-pyrazol-3-yl)[6-methyl-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl]amine 438205-38-0P, (5-Cyclopropyl-1H-pyrazol-3-yl)[6-(morpholin-4-yl)-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl]amine 438205-40-4P, (5-Cyclopropyl-1H-pyrazol-3-yl)[6-(1-methylpiperazin-4-yl)-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl]amine 438205-41-5P, [6-(2,6-Dimethylphenyl)-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-42-6P, [6-(2-Methylphenyl)-2-(naphthalen-2-ylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-43-7P, (5-Methyl-1H-pyrazol-3-yl)[2-(naphthalen-2-ylsulfanyl)-6-phenylpyrimidin-4-yl]amine 438205-44-8P, [2-(4-Isobutyrylylaminophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-46-0P, (5-Methyl-1H-pyrazol-3-yl)[6-phenyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl]amine 438205-47-1P, [2-(4-Cyclopropylcarbonylaminophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-48-2P , (5-Methyl-1H-pyrazol-3-yl)[6-phenyl-2-[[4-(propylsulfonylamino)phenyl]sulfanyl]pyrimidin-4-yl]amine 438205-49-3P, [2-(4-Ethanesulfonylaminophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-50-6P, [2-(4-Acetamidophenylsulfanyl)-6-(2-methylphenyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-51-7P, [2-(4-Isobutylcarbonylaminophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-52-8P , [2-(4-Acetamidophenylsulfanyl)-5-methyl-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-53-9P, [6-(3-Acetamidophenyl)-2-(4-acetamidophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-54-0P, [2-(4-Isopropylsulfonylaminophenylsulfanyl)-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-55-1P , [2-[[4-(2-Dimethylaminoacetylamino)phenyl]sulfanyl]-6-phenylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-56-2P 438205-57-3P 438205-58-4P, [2-Benzylsulfanyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-59-5P 438205-60-8P 438205-61-9P, [2-(4-Acetamidophenylsulfanyl)-6-tert-butylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-62-0P, (5-Cyclopropyl-1H-pyrazol-3-yl)[6-phenyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl]amine 438205-63-1P 438205-64-2P, (5-Methyl-1H-pyrazol-3-yl)[2-[[4-(morpholinosulfonyl)benzyl]sulfanyl]-6-morpholin-4-ylpyrimidin-4-yl]amine 438205-65-3P, [6-(2-Methoxyethylamino)-2-[[4-(morpholinosulfonyl)benzyl]sulfanyl]pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-66-4P, [6-(4-Methylpiperazin-1-yl)-2-[[4-(morpholinosulfonyl)benzyl]sulfanyl]pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-67-5P, [6-Methoxymethyl-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl]-(5-methyl-1H-pyrazol-3-yl)amine 438205-68-6P, [2-(4-Methoxycarbonylphenylsulfanyl)-6-methoxymethylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-69-7P, [2-(3,5-Dimethoxybenzylsulfanyl)-6-morpholin-4-ylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-70-0P, [2-(3,5-Dimethoxybenzylsulfanyl)-6-pyrrolidin-4-ylpyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine 438205-71-1P, (5-Methyl-1H-pyrazol-3-yl)[6-morpholin-4-yl-2-(naphthalene-2-ylmethylsulfanyl)pyrimidin-4-yl]amine 438205-72-2P, [2-(4-Acetamidophenylsulfanyl)pyrimidin-4-yl](5-

methyl-1H-pyrazol-3-yl)amine 438205-73-3P,
[6-(1-Butoxycarbonyl)-2-(4-propionylaminophenylsulfanyl)pyrimidin-4-yl](5-methyl-1H-pyrazol-3-yl)amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438203-35-1 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-36-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(4-methoxyphenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438203-41-9 CAPLUS
CN Acetamide, N-[4-[[4-[4-[3-(dimethylamino)propoxy]phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-45-3 CAPLUS
CN Propanamide, N-[4-[[4-(hydroxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438203-48-6 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-29-9 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-30-2 CAPLUS
CN Benzoic acid, 3-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-31-3 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-32-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-34-6 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-36-8 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-38-0 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-40-4 CAPLUS
CN 4-Pyrimidinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-41-5 CAPLUS
CN 4-Pyrimidinamine, 6-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-42-6 CAPLUS
CN 4-Pyrimidinamine, 6-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-43-7 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenylthio)-6-phenyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-44-8 CAPLUS
CN Propanamide, 2-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-46-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-47-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-48-2 CAPLUS
CN 1-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-49-3 CAPLUS
CN Ethanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-50-6 CAPLUS
CN Acetamide, N-[4-[[4-(2-methylphenyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-51-7 CAPLUS
CN Butanamide, 3-methyl-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-52-8 CAPLUS
CN Acetamide, N-[4-[[5-methyl-4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-53-9 CAPLUS
CN Acetamide, N-[4-[[4-[3-(acetylamino)phenyl]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-54-0 CAPLUS
CN 2-Propanesulfonamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-55-1 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-56-2 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-57-3 CAPLUS
CN 4,6-Pyrimidinediamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(2-methoxyethyl)-N'-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-58-4 CAPLUS
CN 4-Pyrimidinamine, 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-59-5 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-60-8 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-61-9 CAPLUS
CN Acetamide, N-[4-[[4-(1,1-dimethylethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-62-0 CAPLUS
CN Propanamide, N-[4-[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-phenyl-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-63-1 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3-chlorophenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-64-2 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-morpholinyl)-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-65-3 CAPLUS
CN Morpholine, 4-[[4-[[[4-[(2-methoxyethyl)amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-66-4 CAPLUS
CN Morpholine, 4-[[4-[[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-67-5 CAPLUS
CN Propanamide, N-[4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-68-6 CAPLUS
CN Benzoic acid, 4-[[4-(methoxymethyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-69-7 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-70-0 CAPLUS
CN 4-Pyrimidinamine, 2-[[(3,5-dimethoxyphenyl)methyl]thio]-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-71-1 CAPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-2-[(2-naphthalenylmethyl)thio]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-72-2 CAPLUS
CN Acetamide, N-[4-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 438205-73-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[[4-[(1-oxopropyl)amino]phenyl]thio]-, butyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

```
=> => d his

     (FILE 'HOME' ENTERED AT 09:17:43 ON 25 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 09:17:54 ON 25 OCT 2006
L1             STRUCTURE UPLOADED
L2          10 S L1 SSS SAM
L3         179 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 09:19:35 ON 25 OCT 2006
L4          13 S L3

     FILE 'CAOLD' ENTERED AT 09:20:28 ON 25 OCT 2006

=> s l3
L5           0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.44     235.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -9.75

STN INTERNATIONAL LOGOFF AT 09:20:39 ON 25 OCT 2006
```

Application Number [ ] Submit

IDS Flag Clearance for Application 10632428

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Last Modified	Reviewer
M844	2006-08-03	29	Y ☑	2006-10-25 14:04:11.0	DRao
M844	2003-08-01	11	Y ☑	2006-02-02 10:29:09.0	jjohnsen1
Update					